Tested Applications
| Positive IHC detected in | human prostate cancer tissue, human ovary tumor tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
20305-1-AP targets CD47 in WB, IHC, IF, IP, CoIP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag14132 Product name: Recombinant human CD47 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-150 aa of BC010016 Sequence: MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPI Predict reactive species |
| Full Name | CD47 molecule |
| Calculated Molecular Weight | 323 aa, 35 kDa |
| GenBank Accession Number | BC010016 |
| Gene Symbol | CD47 |
| Gene ID (NCBI) | 961 |
| RRID | AB_10732838 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q08722 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CD47, also known as integrin-associated protein (IAP), is a member of the immunoglobulin superfamily containing a five-pass transmembrane attachment. CD47 is heavily glycosylated and widely expressed by hematopoietic and nonhematopoietic cells. CD47 interacts with several membrane integrins and also acts as a receptor for thrombospondin (THBS1). It is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. CD47 also functions as a ligand for signal regulatory protein-α (SIRPα). Upon binding CD47, SIRPα initiates a signaling cascade that results in the inhibition of phagocytosis.
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for CD47 antibody 20305-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
Anti-CD47 antibody (Cat# 20305-1-AP) has 63 total citations appearing in high-impact journals including Nature Communications, Advanced Materials, Advanced Science, Molecular Cancer, Biomaterials, Journal of Controlled Release, Cell Reports Medicine, ACS Applied Materials & Interfaces, and iScience. Associated research fields encompass cancer immunotherapy, biomimetic nanomedicine, tumor immune evasion, macrophage biology, targeted drug delivery, cardiovascular disease, liver fibrosis, atherosclerosis, and acute lung injury.
| Species | Application | Title |
|---|---|---|
Mol Cancer Targeting the CD47-HCK-LGALS9 axis disrupts proliferation-immunosuppression coupling in early-stage endometrial cancer. | ||
Adv Mater Efficient Delivery of Lomitapide Using Hybrid Membrane-Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy | ||
Bioact Mater A closed-loop myocardial infarction theranostic platform activated by macrophage-derived nitric oxide and acidic microenvironment. | ||
J Extracell Vesicles Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy | ||
Nat Commun USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity | ||
J Nanobiotechnology UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte. |
